

**CNS Pharmaceuticals, Inc.**  
**2100 West Loop South, Suite 900**  
**Houston, TX 77027**

December 14, 2023

**VIA EDGAR**

United States Securities and Exchange Commission  
Division of Corporation Finance  
Office of Life Sciences  
100 F Street, N.E.  
Washington, D.C. 20549

**Re: CNS Pharmaceuticals, Inc.**  
**Registration Statement on Form S-1 (the “Registration Statement”)**  
**File No. 333-275973**

Ladies and Gentlemen:

Pursuant to Rule 461 of the Securities Act of 1933, as amended, CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 5:00 P.M. (Eastern Time) on December 18, 2023, or as soon thereafter as possible on such date.

We request that we be notified of such effectiveness by a telephone call to Cavas Pavri at (202) 724-6847 of ArentFox Schiff LLP, and we request that such effectiveness also be confirmed in writing.

Very truly yours,  
**CNS Pharmaceuticals, Inc.**

By: /s/ Christopher Downs  
Name: Christopher Downs  
Title: Chief Financial Officer

cc: Cavas Pavri, ArentFox Schiff LLP